ArticleDermatology and therapy2026
Efficacy of Remibrutinib versus Dupilumab at Early Timepoints in Chronic Spontaneous Urticaria: US Phase 3b Study Design (RECLAIM).
Article in Dermatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06868212 (A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihistamines), which is not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihistamines
Who cites it
2 citing papers in PubMed.
- Targeted Therapy for Antihistamine-Refractory Chronic Spontaneous Urticaria: A Critical Narrative Review and an Evidence-Graded Approach to Agent Selection.Antibodies (Basel, Switzerland) · 2026Review
- Emerging and Newly Approved Therapies for Antihistamine-Refractory Chronic Spontaneous Urticaria: A Narrative Review.Diseases (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRemibrutinib, an oral, highly selective Bruton's tyrosine kinase (BTK) inhibitor, was recently approved by the US Food and Drug Administration (FDA) for the treatment of chronic spontaneous urticaria (CSU). Dupilumab, an interleukin-4 receptor-α monoclonal antibody, was approved by the FDA for CSU in early 2025. Here, we report the design of RECLAIM (NCT06868212), a phase 3b study that aims to compare the efficacy of remibrutinib and dupilumab at early timepoints in patients with symptomatic CSU despite treatment.
methodsThis US-based, multicenter, randomized, double-blind, double-dummy study will include approximately 400 patients with moderate-to-severe CSU who remain symptomatic despite treatment with second-generation H PLANNED OUTCOMES: RECLAIM will evaluate the early efficacy of remibrutinib versus dupilumab in patients with CSU. The study is currently recruiting patients.
trial registrationClinicalTrials.gov identifier, NCT06868212.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.